UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39927 SEASTAR MEDICAL HOLDING CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 85-3681132 (State or ot ...

DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) ("SeaStar Medical" or the "Company"), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and six months ended June 30, 2024 and provides a business update. "Our recent commercial, clinical and corporate achievements have significantly strengthened our company and support an active and excit ...

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Shareholders who purchased shares of ICU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/seastar-medical-loss-submission-form/?id=95127&from=3 CLASS PERI ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Shareholders who purchased shares of ICU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/seastar-medical-loss-submission-form/?id=94063&from=3 CLASS PERI ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in SeaStar stock or options between October 31, 2022 and March 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.far ...

NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in SeaStar Medical Holding Corporation ("SeaStar Medical" or the "Company") (NASDAQ: ICU) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of SeaStar Medical investors who were adversely affected by alleged securities fraud between October 31, 2022 and March 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra- ...

NEW YORK, Aug. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Shareholders who purchased shares of ICU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/seastar-medical-loss-submission-form/?id=93549&from=4 CLASS PERIOD: O ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in SeaStar stock or options between October 31, 2022 and March 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.far ...

If you are a shareholder who purchased or otherwise acquired SeaStar securities during the Class Period, you have until September 6, 2024 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained atwww.pomerantzlaw.com. To discuss this action, contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by email are encouraged to include their mailing address, telephone number, and the number of shares ...

Nestor Jaramillo, President and CEO of Nuwellis, shared his thoughts on this milestone: "We are thrilled to introduce QUELIMMUNE to critically ill pediatric patients in need. This marks a significant step forward in Nuwellis' mission to execute our pediatric business development strategy. By partnering with SeaStar Medical, we are committed to bringing this groundbreaking therapy to U.S. healthcare providers, offering new hope to children suffering from severe immune system reactions." About Nuwellis Dr. St ...